The National Society of Genetic Counselors (NSGC) supports the U.S. Supreme Court's unanimous ruling in Association for Molecular Pathology v Myriad Genetics, Inc. which states that while synthetic complementary DNA is patent eligible, naturally occurring human DNA sequences may not be patented. NSGC believes that this ruling facilitates competitive pricing of genetic testing to benefit the public and supports both genomic medicine services and the development of novel ideas and technologies. (Reaffirmed - April 2019)

Do you have positive or constructive feedback regarding this statement? Please submit a comment to be considered during by the NSGC Position Statement Workgroup (PSW) when the statement is up for review. Comments can be submitted anonymously. Log-in is required as this feedback option is available only to NSGC members. Please note that submitting feedback is unlikely to lead to a direct response from the PSW. Comments will be considered when the position statement is reviewed.

Back to Position Statements